Evidence map›Paper›PMID 40100107›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025

Exploring EGPA: Clinical perspectives on peripheral eosinophilia and lung involvement with real-life data.

Nesrin Ocal, Deniz Dogan, Ramazan Ocal, Beste Arikan, Sebnem Alsat Guray, Aysuna Dincer, Mehmet Agilli, Yakup Arslan, Canturk Tasci

Abstract read
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nesrin OcalHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Deniz DoganHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Ramazan OcalIstinye University, Liv Hospital, Department of Hematology, Ankara, Turkey.
Beste ArikanHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Sebnem Alsat GurayHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Aysuna DincerHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Mehmet AgilliHealth Sciences University, Gulhane Faculty of Medicine, Department of Biochemistry, Ankara, Turkey.
Yakup ArslanHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.
Canturk TasciHealth Sciences University, Gulhane Faculty of Medicine, Department of Pulmonology, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe role of eosinophils in acute and chronic lung diseases becomes more evident day by day. The aim of this study is to analyze the guiding role of peripheral eosinophilia in the diagnosis of lung diseases and to present pulmonologists' perspective on EGPA with old and new diagnostic criteria through real-life data.  Patients and Methods: In this retrospective observational cohort, the files of patients who presented to the chest diseases department with pulmonary symptoms and peripheral eosinophilia between 2017-2023 were investigated. The diagnoses of the patients and their eosinophilia severity were examined. All the cases were reviewed according to the old and new diagnostic criteria for EGPA.  Results: Among the 1567 patients with pulmonary symptoms and peripheral eosinophilia, pulmonary infection was the most common cause, followed by asthma and COPD. Mild eosinophilia was detected in the majority of the patients (90.5%). The highest mean eosinophil counts were observed in malignancies, hematological diseases and rheumatological diseases (including EGPA), respectively. Eosinophilia severities had significant difference between the diagnostic subgroups (p<0.001). The data were revised for EGPA with old and current diagnostic criteria. The false positivity rate of the old criteria was found to be significantly higher than the correctly applied current criteria (92.8% and 33.3%). Proper application of the current classification criteria regarding EGPA, which is among the causes of severe eosinophilia, will prevent unnecessary tests in this regard.

Identifiers

PMID40100107
PMCPMC12013690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.